{"id":405730,"date":"2020-12-28T07:33:21","date_gmt":"2020-12-28T12:33:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=405730"},"modified":"2020-12-28T07:33:21","modified_gmt":"2020-12-28T12:33:21","slug":"navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/","title":{"rendered":"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter<\/b><\/p>\n<p>DUBLIN, Ohio&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nNavidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment Malcolm G. Witter to its Board of Directors.\n<\/p>\n<p>\nMr. Witter brings decades of financial and corporate governance experience to the board. He currently serves as a corporate development leader for USI Insurance Services (\u201cUSI\u201d) and is responsible for acquiring independent insurance agencies. Prior to USI, Mr. Witter held roles at multiple financial institutions including Bear Stearns, EF Hutton, and Dean Witter. Mr. Witter received his MBA from the Stanford Graduate School of Business and he also serves as the President of the Dean Witter Foundation.\n<\/p>\n<p>\nJed Latkin, Navidea\u2019s CEO said, &#8220;We are fortunate to have Malcolm Witter join Navidea\u2019s Board of Directors. Malcolm&#8217;s expertise in M&amp;A, corporate finance, and corporate governance better equip the Company as it moves into the new year. We look forward to Malcolm\u2019s input and engagement in guiding Navidea toward future development and success.\u201d\n<\/p>\n<p><b>About Navidea<\/b><\/p>\n<p>\nNavidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept\u2122 platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea\u2019s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea\u2019s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company\u2019s pipeline through global partnering and commercialization efforts. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.navidea.com&amp;esheet=52353709&amp;newsitemid=20201228005127&amp;lan=en-US&amp;anchor=www.navidea.com&amp;index=1&amp;md5=750badf347e49a1aa1ada7a8af617b5e\">www.navidea.com<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201228005127\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201228005127\/en\/<\/a><\/span><\/p>\n<p>\nNavidea Biopharmaceuticals, Inc.<br \/>\n<br \/>Jed Latkin, CEO<br \/>\n<br \/>614-973-7490<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jlatkin@navidea.com\">jlatkin@navidea.com<\/a><\/p>\n<p>\nJoel Kaufman<br \/>\n<br \/>Chief Business Officer<br \/>\n<br \/>614-822-2372<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jkaufman@navidea.com\">jkaufman@navidea.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Ohio United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201228005127\/en\/389794\/3\/navidea_cmyk.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter DUBLIN, Ohio&#8211;(BUSINESS WIRE)&#8211; Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment Malcolm G. Witter to its Board of Directors. Mr. Witter brings decades of financial and corporate governance experience to the board. He currently serves as a corporate development leader for USI Insurance Services (\u201cUSI\u201d) and is responsible for acquiring independent insurance agencies. Prior to USI, Mr. Witter held roles at multiple financial institutions including Bear Stearns, EF Hutton, and Dean Witter. Mr. Witter received his MBA from the Stanford Graduate School of Business and he also serves as the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-405730","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter DUBLIN, Ohio&#8211;(BUSINESS WIRE)&#8211; Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment Malcolm G. Witter to its Board of Directors. Mr. Witter brings decades of financial and corporate governance experience to the board. He currently serves as a corporate development leader for USI Insurance Services (\u201cUSI\u201d) and is responsible for acquiring independent insurance agencies. Prior to USI, Mr. Witter held roles at multiple financial institutions including Bear Stearns, EF Hutton, and Dean Witter. Mr. Witter received his MBA from the Stanford Graduate School of Business and he also serves as the &hellip; Continue reading &quot;Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-28T12:33:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter\",\"datePublished\":\"2020-12-28T12:33:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/\"},\"wordCount\":525,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/\",\"name\":\"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-28T12:33:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/","og_locale":"en_US","og_type":"article","og_title":"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter - Market Newsdesk","og_description":"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter DUBLIN, Ohio&#8211;(BUSINESS WIRE)&#8211; Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment Malcolm G. Witter to its Board of Directors. Mr. Witter brings decades of financial and corporate governance experience to the board. He currently serves as a corporate development leader for USI Insurance Services (\u201cUSI\u201d) and is responsible for acquiring independent insurance agencies. Prior to USI, Mr. Witter held roles at multiple financial institutions including Bear Stearns, EF Hutton, and Dean Witter. Mr. Witter received his MBA from the Stanford Graduate School of Business and he also serves as the &hellip; Continue reading \"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-28T12:33:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter","datePublished":"2020-12-28T12:33:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/"},"wordCount":525,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/","name":"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-28T12:33:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201228005127r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-malcolm-witter\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=405730"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405730\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=405730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=405730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=405730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}